Rasagiline is an irreversible MAO-B inhibitor that is FDA-approved for treatment of Parkinson’s disease, and isradipine is an L-type calcium channel inhibitor that is an FDA-approved dihydropyridine antihypertensive medication. This evidence concerns the gene MAOB and Parkinson disease.